// App-Quantinova.ai

1919 : Risk of hepatitis B virus (HBV) infection and re‐activation after discontinuation of tenofovir and/or lamivudine as part of antiretroviral therapy in a high HBV endemicity setting

Researchers

Presenter

  • ADAM Abdullahi

Principal Investigators

  • Apostolos Beloukas

  • Olga Mafotsing Fopoussi

  • Judith Torimiro

  • Charles Kouanfack

  • Anna M. Geretti

Medical Centers

  • University of Liverpool, Liverpool, United Kingdom

  • CIRCB, Yaounde, Cameroon

  • Yaounde Military Hospital, Yaounde, Cameroon

Locations

  • United Kingdom

  • Cameroon

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis B

Biomarkers

  • Hepatitis B surface antigen

  • Hepatitis B e antigen

  • Serum hepatitis B virus DNA

Drug/Treatment

  • Lamivudine

  • Ritonavir

  • Tenofovir disoproxil fumarate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved